Strs Ohio Makes New Investment in Pfizer Inc. $PFE

Key Points

• Strs Ohio has made a new investment in Pfizer Inc., acquiring approximately 1.97 million shares valued at about $50 million during the first quarter.
• Analysts have set a consensus price target for Pfizer at $28.12, with ratings varying from "Strong Buy" to "Sell."
• Pfizer recently reported earnings of $0.78 per share, exceeding estimates, along with a quarterly dividend of $0.43 per share, reflecting a yield of 7.0%.

Strs Ohio acquired a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 1,971,914 shares of the biopharmaceutical company's stock, valued at approximately $49,968,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Gould Capital LLC lifted its stake in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. acquired a new position in shares of Pfizer in the first quarter worth about $27,000. Bayforest Capital Ltd acquired a new stake in Pfizer during the first quarter valued at approximately $28,000. North Capital Inc. acquired a new stake in Pfizer during the first quarter valued at approximately $28,000. Finally, Bernard Wealth Management Corp. acquired a new stake in Pfizer during the fourth quarter valued at approximately $30,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Morgan Stanley upped their price objective on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 6th. Citigroup upped their target price on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. HSBC lowered their target price on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a report on Monday, May 19th. Bank of America upped their target price on Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Finally, Berenberg Bank lowered their target price on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $28.12.

Pfizer Stock Performance

PFE opened at $24.59 on Thursday. The company has a market capitalization of $139.79 billion, a price-to-earnings ratio of 13.08, a price-to-earnings-growth ratio of 0.88 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43. The business has a 50 day moving average price of $24.83 and a two-hundred day moving average price of $24.33.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. The ex-dividend date was Friday, July 25th. Pfizer's dividend payout ratio is 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.